The study is investigating the safety and tolerability of LX9851, how it moves through the body and its physiological and ...
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic ...
THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College of ...
Zacks Investment Research on MSN
LXRX stock up as NVO initiates phase I study of partnered obesity drug
Shares of Lexicon Pharmaceuticals LXRX gained 5.1% on Monday after the company announced that its partner, Novo Nordisk NVO, ...
Joining me today are Dr. Michael S. Exton, Lexicon Pharmaceuticals, Inc.'s Chief Executive Officer and Director; Dr. Craig B.
Investors in Lexicon Pharmaceuticals are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter. It's wort ...
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is one of the High-Flying Penny Stocks to Buy. On March 12, H.C. Wainwright ...
Lexicon Pharmaceuticals (NASDAQ:LXRX) outlined progress across three late-stage programs and reported sharply lower operating ...
Lexicon Pharmaceuticals won't take no for an answer. The Texas pharma—convinced of the value of its diabetes candidate sotagliflozin—has clapped back at its latest rejection from the FDA, asking to be ...
Investing in biotech stocks is a risky endeavor, but sometimes you can eke out a return without facing as much potential trouble as usual. By identifying companies that are likely to report rapid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results